Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases

Patients with an epidermal growth factor receptor (EGFR) mutation are usually administered EGFR‐tyrosine kinase inhibitors (TKIs) as standard‐of‐care treatment. However, acquired resistance occurs between 9 and 13 months. The T790M‐resistant mutations are the most common, and osimertinib has been fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respirol Case Rep
Main Authors: Takeda, Takayuki, Itano, Hideki, Takeuchi, Mayumi, Nishimi, Yurika, Saitoh, Masahiko, Takeda, Sorou
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2017
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412970/
https://ncbi.nlm.nih.gov/pubmed/28469919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.241
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados